Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference
11 January 2022 - 1:00AM
Artelo Biosciences, Inc. (NASDAQ:
ARTL), a clinical stage pharmaceutical company developing
therapeutics that modulate endogenous signaling pathways, including
the endocannabinoid system, today announced that it will be
participating at the H.C. Wainwright BioConnect 2022 Conference
being held virtually January 10-13, 2022.
Key members of Artelo’s leadership team, Andy
Yates, PhD, Senior Vice President and Chief Scientific Officer, and
Prof. Saoirse O’Sullivan, PhD, Vice President of Translational
Sciences, are scheduled to participate in a live panel discussion
entitled, “The Endocannabinoid System: one system, so many
opportunities” on Tuesday, January 11, 2022 at 3:00 PM Eastern
Time. Dr. Yates and Dr. O’Sullivan will provide an overview of the
endocannabinoid system and its relevance in drug development as
well as discuss Artelo’s pipeline of drug candidates. The panel
will be hosted by Vernon Bernardino, Senior Healthcare Analyst at
H.C. Wainwright, and can be accessed here: Artelo Panel
Discussion.
Additionally, Gregory Gorgas, President and
Chief Executive Officer of Artelo Biosciences, will present the
outlook for the Company during the conference that will be
available on-demand to registered attendees via the conference
platform beginning Monday, January 10, 2022 at 7:00 AM Eastern
Time.
The webcast of the Company’s presentation can be
accessed here: Artelo Company Presentation as of 7:00 AM
Eastern Time on Thursday, January 13, 2022 and on the investor
relations section of Artelo’s website at https://ir.artelobio.com/
following the conclusion of the conference.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage
pharmaceutical company dedicated to the development and
commercialization of proprietary therapeutics that modulate lipid
signaling pathways, including the endocannabinoid system. Artelo is
advancing a portfolio of broadly applicable product candidates
designed to address significant unmet needs in multiple diseases
and conditions, including anorexia, cancer, PTSD, pain, and
inflammation. Led by proven pharmaceutical executives collaborating
with respected researchers and technology experts, Artelo applies
leading edge scientific, regulatory, and commercial discipline to
develop high-impact therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Investor Relations
Contact:Crescendo Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Apr 2023 to Apr 2024